ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,379.40
-1.79%
S&P ASX All Technology
3,901.70
-2.06%
Brent Oil
75.79
-0.74%
US Dollar vs AUD
1.62725
-0.01%
Bitcoin
97,026.20
-0.69%
Pepperstone
Advertisement
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Immunic Inc (IMUX)

  7. Immunic Inc (IMUX) News

IMUX

Immunic (IMUX)

Immunic Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IMUX
DateTimeSourceHeadlineSymbolCompany
14/01/202500:32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMUXImmunic Inc
07/01/202522:30PR Newswire (US)Immunic Highlights 2024 Accomplishments and Upcoming MilestonesNASDAQ:IMUXImmunic Inc
19/12/202408:36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMUXImmunic Inc
10/12/202400:30Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:IMUXImmunic Inc
07/12/202409:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMUXImmunic Inc
07/12/202409:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMUXImmunic Inc
07/12/202409:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMUXImmunic Inc
07/12/202409:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMUXImmunic Inc
07/12/202409:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMUXImmunic Inc
26/11/202422:30PR Newswire (US)Immunic, Inc. to Participate in Investor Conference in DecemberNASDAQ:IMUXImmunic Inc
15/11/202409:33Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:IMUXImmunic Inc
14/11/202422:58Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:IMUXImmunic Inc
14/11/202406:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMUXImmunic Inc
13/11/202422:30PR Newswire (US)Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & HepatologyNASDAQ:IMUXImmunic Inc
13/11/202401:31Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:IMUXImmunic Inc
07/11/202423:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMUXImmunic Inc
07/11/202422:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMUXImmunic Inc
07/11/202422:30PR Newswire (US)Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:IMUXImmunic Inc
31/10/202421:30PR Newswire (US)Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate UpdateNASDAQ:IMUXImmunic Inc
29/10/202421:30PR Newswire (US)Immunic to Participate in Industry, Scientific and Investor Conferences in NovemberNASDAQ:IMUXImmunic Inc
22/10/202421:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMUXImmunic Inc
22/10/202421:30PR Newswire (US)Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple SclerosisNASDAQ:IMUXImmunic Inc
18/09/202420:30PR Newswire (US)Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple SclerosisNASDAQ:IMUXImmunic Inc
11/09/202406:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMUXImmunic Inc
04/09/202420:30PR Newswire (US)Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID SyndromeNASDAQ:IMUXImmunic Inc
03/09/202422:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMUXImmunic Inc
28/08/202420:30PR Newswire (US)Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in SeptemberNASDAQ:IMUXImmunic Inc
08/08/202421:17Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMUXImmunic Inc
08/08/202420:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMUXImmunic Inc
08/08/202420:30PR Newswire (US)Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:IMUXImmunic Inc
 Showing the most relevant articles for your search:NASDAQ:IMUX

Your Recent History

ASX
BHP
BHP
NYSE
KO
Coca Cola
ASX
MQG
Macquarie
NASDAQ
MSFT
Microsoft
FX
AUDCAD
AUD vs CAD
ASX
RIO
Rio Tinto
ASX
XTO
S&P ASX 100
ASX
ANZ
Australia And New Zealan...
COIN
SOLUSD
Solana
NASDAQ
AMZN
Amazon.com
CCOM
SILVER
SILVER
ASX
XJO
S&P ASX 200
ASX
CSL
CSL
NYSE
MCD
McDonalds
ASX
XFL
S&P ASX 50
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads